"Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review." by Yolcar Chamorro

Selected Works of Ana Cristina Sandoval Leon

Article

Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.

All Publications

Yolcar Chamorro, Miami Cancer Institute
Ana Sandoval Leon, Miami Cancer Institute
Manmeet Ahluwalia, Miami Cancer Institute
Reshma Mahtani, Miami Cancer Institute
Naomi Dempsey, Miami Cancer Institute

Publication Date

6-2-2023

Presented At:

ASCO

Content Type

Poster

Additional Authors:

Additional authors and institutional affiliations

Citation Information

Yolcar Chamorro, Ana Sandoval Leon, Manmeet Ahluwalia, Reshma Mahtani, et al.. "Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review." (2023)
Available at: http://works.bepress.com/anacristina-sandovalleon/30/